U.S. stock night trading opens with fluctuations: Battalion Oil rises 9.23% in night trading; NRG Energy rises 8.52% in night trading

U.S. Stock Night Trading Opening Movements Battalion Oil rose 9.23% in night trading, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. NRG Energy rose 8.52% in night trading. Based on recent news, On February 21, Jefferies analysts maintained a buy rating on NRG Energy with a target price of $181. The analysts' positive assessment boosted market confidence, driving the stock price up. On February 20, NRG Energy's quarterly earnings report showed actual earnings exceeded market expectations. Specific data indicated that the earnings per share for the third quarter of 2025 was $2.75, surpassing the expected $2.10, resulting in a 31% surprise. On February 20, NRG Energy performed excellently in multiple quarterly reports, particularly with an earnings per share of $2.31 for the first quarter of 2024, exceeding the expected $0.66, with a surprise magnitude of 248.2%. This series of strong earnings data further boosted investor confidence. The market reacted positively to NRG Energy's earnings performance, driving the stock price up. Top Gainers in U.S. Stock Night Trading Mace Property rose 49.82% in night trading, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Vanda Pharmaceuticals rose 42.01% in night trading. Based on recent key news: On February 20, the U.S. FDA approved Vanda Pharmaceuticals' antipsychotic drug Bysanti for the treatment of schizophrenia and acute bipolar I disorder. This approval marks an important milestone for Vanda Pharmaceuticals, driving the stock price up. Source: Reuters On February 21, Vanda Pharmaceuticals announced plans to launch Bysanti in the U.S. in the third quarter of this year. This news further enhanced market confidence in the company's future growth, and the stock price continued to rise. Source: Reuters On February 21, the approval of Bysanti came with a serious warning from the FDA regarding the increased risk of death in elderly patients with dementia-related psychosis. Despite the risks, the market remains optimistic about the potential of the new drug, and the stock price rose significantly. Source: Reuters The demand for mental health medications is strong, and risks need to be monitored. Lixiang Education rose 14.35% in night trading, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation